Merck, Novo, and Novartis are moving deeper into early-stage China partnering, with multiple deals now structured around assets earlier in development than in prior cycles, according to BioCentury’s data byte. The report says the companies are paying at least $300 million per deal, reflecting renewed competition for differentiated modalities and preclinical/early clinical programs in oncology, including cancer antibodies. For biotech investors, the key development is that the bar for “asset maturity” appears to be falling—at least in deal terms—while total upfront economics remain large. That shift can accelerate translation for smaller innovators, but it also raises execution risk for programs that are still finding their clinical footing. The update also reinforces that China partnering is broadening beyond blockbuster antibody bets into more diverse early assets, making partnering timelines and readouts more consequential for follow-on financing and BD strategy globally.